NMN at $100/Month: What Are You Actually Buying?

Nicotinamide mononucleotide (NMN) is a building block your body uses to make NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in DNA repair, mitochondrial energy production, and circadian rhythm. NAD+ does fall with age, and that is real. Whether taking NMN reverses that in any meaningful way in humans — and whether the reversal actually improves how you feel, function, or live — is where the science is still well short of the marketing.

The Animal Data Is Compelling but Insufficient

Mouse studies show NMN can reverse parts of vascular aging, improve muscle endurance, raise insulin sensitivity, and extend lifespan in some models. These findings drove the commercial market. The problem: mice convert NMN to NAD+ more efficiently than humans, and longevity findings rarely translate cleanly across species. Dose extrapolation from mouse to human is notoriously unreliable.

Human Trials: Early and Limited

As of April 2026, fewer than 20 completed RCTs of NMN in humans are published. The two most-cited:

Igarashi 2022 (PMID 35927255) randomized 42 healthy older Japanese men to 250 mg/day NMN or placebo for 6 or 12 weeks. NMN raised blood NAD+ and produced nominally significant improvements in gait speed and left-hand grip strength. The authors note these need to be confirmed in larger trials. Body composition did not change.

Yoshino 2021 (PMID 33888596), published in Science, was a 10-week placebo-controlled trial of 25 postmenopausal women with prediabetes who were overweight or obese. The dose was 250 mg/day (not the 600 mg figure that has circulated in media). The primary endpoint — muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp — improved with NMN versus placebo. A published comment (Brenner 2021, PMID 34326206) flagged a baseline imbalance in liver fat between groups, which the authors addressed without reversing the conclusion. The trial does not show benefit in healthy adults or men.

What no human trial has shown: longer life, lower rates of dementia, heart disease, or cancer, or any of the aging-related outcomes the marketing implies. NMN reliably raises NAD+ in blood — but moving a biomarker is not the same as a clinical benefit.

Cost Versus Uncertainty

Quality NMN runs $80–$150 per month. At that price you are paying for early-stage science and a story. Nicotinamide riboside (NR) is a related NAD+ precursor with a larger human trial base and is usually 30–50% cheaper. Neither has proven longevity benefits in humans. Until larger, longer trials with clinical endpoints are completed, NMN remains speculative for most people.